Home    Back

Tasimelteon    (DrugBank: Tasimelteon)

1 disease
IDDisease name (Link within this page)Number of trials
202Smith-Magenis syndrome2

202. Smith-Magenis syndrome    [ 10 clinical trials,   10 drugs,   (DrugBank: 4 drugs),   4 drug target genes,   6 drug target pathways]
Searched query = "Smith-Magenis syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 10 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02776215
(ClinicalTrials.gov)		September 201616/5/2016Study of the Pharmacokinetics and Safety of Tasimelteon in Children and AdolescentsOpen-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and AdolescentsCircadian Rhythm Sleep Disorders;Non-24 Hour Sleep-Wake Disorder;Autism Spectrum Disorder;Smith-Magenis SyndromeDrug: tasimelteonVanda PharmaceuticalsNULLRecruiting3 Years17 YearsAll24Phase 1United States
2NCT02231008
(ClinicalTrials.gov)		September 201529/8/2014Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMSSmith-Magenis Syndrome;CircadianDrug: tasimelteonVanda PharmaceuticalsNULLRecruiting16 Years65 YearsBoth48Phase 2;Phase 3United States